Vaccination against COVID-19 in patients with inflammatory bowel diseases

Abstract

The novel coronavirus infection (COVID-19) is characterized by a high incidence of damage not only to the bronchopulmonary system, but also to the gastrointestinal tract. The problem of patients with bowel diseases was reviewed in this research the context of the COVID-19 pandemic and the importance of vaccination this group of patients was reflected and approaches to it were described.

The analysis of biomedical literature data on the problem of vaccination of patients with intestinal diseases against COVID-19 was carried out.

Keywords:inflammatory bowel diseases; vaccination; vaccines; postvaccinal immunity; SARS-CoV-2; COVID-19

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

Contribution. Concept and design of the lecture – Kostinov M.P.; the collection and processing of the material – Khasanova А.А., Cherdantsev А.Р.; writing a text – Khasanova А.А., Soloveva I.L., Cherdantsev А.Р.; editing – Kostinov M.P., Soloveva I.L.

For citation: Khasanova А.А., Kostinov М.Р., Soloveva I.L., Cherdantsev A.P. Vaccination against COVID-19 in patients with inflammatory bowel diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (3): 125–9. DOI: https://doi.org/10.33029/2305-3496-2022-11-3-125-129

References

1.Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5 (4): 536–44. DOI: https://doi.org/10.1038/s41564-020-0695-z

2. WHO. Director-General’s Opening Remarks at the Media Briefing on COVID-19. Geneva, Switzerland: World Health Organization, 2020. URL: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

3. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). URL: https://coronavirus.jhu.edu/map.html

4. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10 223): 497–506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

5. Li X., Geng M., Peng Y., et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020; 10 (2): 102–8. DOI: https://doi.org/10.1016/j.jpha.2020.03.001

6. Chatterjee S.K., Saha S., Munoz M.N.M. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci. 2020; 7: 196. DOI: https://doi.org/10.3389/fmolb.2020.00196

7. Fagni F., Simon D., Tascilar K., et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021; 3 (10): 724–36. DOI: https://doi.org/10.1016/S2665-9913(21)00247-2

8. Garcia Garrido H.M., Grobusch M.P., D’Haens G.R.A.M., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2021; 6 (7): 523. DOI: https://doi.org/10.1016/S2468-1253(21)00148-5

9. Najm A., Alunno A., Mariette X., et al. Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open. 2021; 7 (1): e001549. DOI: https://doi.org/10.1136/rmdopen-2020-001549

10. Furer V., Rondaan C., Heijstek M., et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5 (2): e001041. DOI: https://doi.org/10.1136/rmdopen-2019-001041

11. Mehta B., Pedro S., Ozen G., et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019; 5 (1): e000935. DOI: https://doi.org/10.1136/rmdopen-2019-000935

12. Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion Coronavirus and IBD Reporting Database: Current Data. URL: https://covidibd.org/current-data/

13. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5 (1): 17–30. DOI: https://doi.org/10.1016/S2468-1253(19)30333-4

14. Ahlawat S., Asha, Sharma K.K. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection. Virus Res. 2020l; 286: 198103. DOI: https://doi.org/10.1016/j.virusres.2020.198103

15. Mao R., Qiu Y., He J.S., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (7): 667–78. DOI: https://doi.org/10.1016/S2468-1253(20)30126-6

16. Ungaro R.C., Brenner E.J., Gearry R.B., et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021; 70 (4): 725–32. DOI: https://doi.org/10.1136/gutjnl-2020-322539

17. Bezzio C., Saibeni S., Variola A., et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020; 69 (7): 1213–7. DOI: https://doi.org/10.1136/gutjnl-2020-321411

18. Quartuccio L., Zabotti A., Del Zotto S., et al. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Adv Res. 2018; 15: 87–93. DOI: https://doi.org/10.1016/j.jare.2018.09.003

19. Kumar A., Quraishi M.N., Segal J.P., et al. COVID-19 vaccinations in patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020; 5 (11): 965–6. DOI: https://doi.org/10.1016/S2468-1253(20)30295-8

20. D’Amico F., Rabaud C., Peyrin-Biroulet L., Danese S. SARS-CoV-2 vaccination in IBD: more pros than cons. Nat Rev Gastroenterol Hepatol. 2021; 18 (4): 211–3. DOI: https://doi.org/10.1038/s41575-021-00420-w

21. Alexander J.L., Kennedy N.A., Lees C.W., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021; 6 (3): 218–24. DOI: https://doi.org/10.1016/S2468-1253(21)00024-8

22. Siegel C.A., Melmed G.Y., McGovern D.P.B., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021; 70 (4): 635–40. DOI: https://doi.org/10.1136/gutjnl-2020-324000

23. Ferretti F., Cannatelli R., Benucci M., et al. How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: an expert opinion by IMIDs Study Group. Front Immunol. 2021; 12: 656362. DOI: https://doi.org/10.3389/fimmu.2021.656362

24. Melmed G.Y., Rubin D.T., McGovern D.P.B. Winter is coming! Clinical, immunologic, and practical considerations for vaccinating patients with inflammatory bowel disease during the Coronavirus disease – 2019 pandemic. Gastroenterology. 2021; 160 (3): 639–44. DOI: https://doi.org/10.1053/j.gastro.2020.10.013

25. Priority vaccination of respiratory infections during the SARSCOV-2 pandemic and after its completion. A guide for physicians. In: M.P. Kostinov, A.G. Chuchalin (eds). Moscow: MDV, 2020: 32 p. (in Russian)

26. Kostinov M.P., Svitich O.A., Markelova E.V. Potential COVID-19 immunoprophylaxis in high-risk groups. Temporary allowance for physicians. Moscow: MDV, 2020: 64 p. (in Russian)

27. Guidelines for clinical immunology in respiratory medicine. 2nd ed. In: M.P. Kostinov, A.G. Chuchalin (eds). Moscow: MDV, 2018: 304 p. (in Russian)

28. Kostinov M.P. Vaccination of adults – from strategy to tactics. A guide for physicians. Moscow: MDV, 2020: 248 p. (in Russian)

29. Melmed G.Y., Ippoliti A.F., Papadakis K.A., et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006; 101 (8): 1834–40. DOI: https://doi.org/10.1111/j.1572-0241.2006.00646.x

30. Rahier J.F., Magro F., Abreu C., et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014; 8 (6): 443–68. DOI: https://doi.org/10.1016/j.crohns.2013.12.013

31. Huth K., Benchimol E.I., Aglipay M., Mack D.R. Strategies to improve influenza vaccination in pediatric inflammatory bowel disease through education and access. Inflamm Bowel Dis. 2015; 21 (8): 1761–8. DOI: https://doi.org/10.1097/MIB.0000000000000425

32. Apte M., Reich J., Farraye F.A. Vaccinations for patients with inflammatory bowel disease: an updated review. Pract Gastroenterol. 2018; 42 (12): 64–74.

33. Fiorino G., Peyrin-Biroulet L., Naccarato P., et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012; 18 (6): 1042–7. DOI: https://doi.org/10.1002/ibd.21800

34. Wong S.Y., Dixon R., Martinez P.V., et al. Serologic response to messenger RNA Coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies. Gastroenterology. 2021; 161 (2): 715–8.e4. DOI: https://doi.org/10.1053/j.gastro.2021.04.025

35. Folegatti P.M., Ewer K.J., Aley P.K. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396: 467–78.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»